Comparative Study of Anti-inflammatory Effects of Rosiglitazone and Pioglitazone with Diclofenac Sodium in Carageenan Induced Rat Hind Paw Oedema

ABTRACT Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARγ), widely used to treat type 2 diabetes mellitus, have been shown to have anti-inflammatory action in some animal models. This study is carried out to evaluate the anti-inflammatory activity of rosiglitazone & Pioglitazone with the standard drug Diclofenac sodium (NSAID). Carageenan is used for inducing inflammation in rats hind paw. Paw volume is measured before and after 0 & 3 hrs by using simple mercury plethysmograph. The percentage inhibition with Diclofenac sodium 5mg/kg is 24.50%, 10mg/kg is 36.76% & 15mg/kg is showing the highest inhibition of 49.01%. Rosiglitazone is showing the percentage inhibition of 20.34%, 30.63% & 40.80% with the respective doses of 0.12mg/kg, 0.24mg/kg & 0.36mg/kg. Pioglitazone shows the least percentage inhibition of 16.29%, 28.55% &38.72% at a concentration of 0.30mg/kg, 0.45mg/kg & 0.60mg/kg respectively. Our study has shown that TZDs have definitive anti-inflammatory effect which was significant with Rosiglitazone. As TZDs act on PPARγ, it has been shown to have anti-inflammatory effect by PPAR dependent and independent mechanisms. They particularly enhance COX-2 expression.